Zoran's key focus is to provide strategic biostatistical input on program and portfolio optimization strategies by supporting methodologies to decrease program cost, to reduce the time to submission, and to increase the probability that the drug development programs will be successful.
Zoran's key focus is to provide strategic biostatistical input on program and portfolio optimization strategies by supporting methodologies to decrease program cost, to reduce the time to submission, and to increase the probability that the drug development programs will be successful.
Charles Persinger joined Eli Lilly and Company in 2002 after receiving his MBA from Duke University. He currently works in Lilly's Decision Sciences department and heads the group's decision consulting practice, leads consulting projects and works in portfolio management and R&D strategy.
Nitin Patel has a Ph.D. from MIT where he has been a visiting professor for over a decade. He is a Fellow of the American Statistical Association. He co-founded Cytel with Cyrus Mehta in 1987 and has served as a member of PhRMA and DIA scientific working groups on adaptive trials.
Description
This session will demonstrate an integrated, value-driven approach as a basis for pharmaceutical portfolio planning and management. In this approach, decisions are defined such that the expected value of pharmaceutical portfolios is maximized.
Learning Objectives: Perform a value-driven approach for planning and management of pharmaceutical portfolios Demonstrate that an integrated approach is necessary in order to maximize the value of pharmaceutical portfolios.